Skip to main content
. 2020 Apr 24;12(8):7465–7479. doi: 10.18632/aging.103094

Table 5. Subgroup multivariate analysis of clinical parameters for 189037 and survival outcomes.

Parameters Subgroup Genotype Disease-free survival Overall survival
Event/No. MST (month) Pa HR*(95%CI) Pb Event/No. MST (month) Pa HR*(95%CI) Pb
rs189037
Smoking Yes AA 24/71 - 1.00 24/71 43.5
AG 121/214 24.5 0.014 1.61(0.97-2.66) 0.063 122/214 34.6 0.055 1.31(0.78-2.19) 0.309
GG 43/85 24.1 0.039 1.67(1.06-2.60) 0.023 37/85 31.8 0.166 1.90(1.22-2.95) 0.004
AG+GG 164/299 24.5 0.012 1.65(1.08-2.55) 0.022 159/299 32.1 0.010 1.71(1.11-2.63) 0.015
No AA 26/94 59.3 1.00 21/94 -
AG 70/169 40.4 0.184 1.40(1.09-2.0) 0.046 70/169 36.9 0.095 1.08(0.58-2.03) 0.800
GG 25/87 61.4 0.017 1.05(1.01-1.83) 0.035 19/87 - 0.027 1.78(1.09-2.90) 0.021
AG+GG 95/256 44.5 0.015 1.29(1.13-2.00) 0.025 89/256 42.9 0.025 1.57(1.09-2.53) 0.045
Histology SCC AA 28/45 22.7 1.00 14/45 73.5 1.00
AG 49/80 23.5 0.836 0.62(0.33-1.16) 0.136 35/80 32.1 0.353 0.62(0.26-1.47) 0.276
GG 15/33 - 0.153 0.95(0.60-1.51) 0.832 8/33 - 0.383 1.34(0.72-2.49) 0.354
AG+GG 64/113 22.7 0.110 1.56(0.90-2.72) 0.115 43/113 38.1 0.067 1.98(0.64-4.190 0.073
ADC AA 51/90 22.5 1.00 33/90 64.3 1.00
AG 107/178 20.7 0.034 1.73(1.17-2.56) 0.006 102/178 31.5 0.089 0.65(0.38-1.11) 0.653
GG 33/90 43.1 0.007 1.80(1.16-2.78) 0.009 23/90 58.4 0.000 1.46(0.99-2.170 0.057
AG+GG 140/268 21.5 0.003 1.75(1.20-2.55) 0.003 125/268 34.6 0.002 2.01(1.29-3.13) 0.002
Other AA 15/37 33.3 1.00 9/37 - 1.00
AG 65/125 28.9 0.271 0.92(0.55-1.51) 0.729 55/125 36.9 0.318 1.41(0.61-3.25) 0.426
GG 20/42 24.7 0.154 0.64(0.33-1.25) 0.194 14/42 - 0.995 1.80(0.89-3.65) 0.101
AG+GG 85/167 30.8 0.505 0.85(0.52-1.38) 0.508 69/167 37.8 0.629 1.15(0.65-2.06) 0.631
Stage IIIA AA 25/90 58.6 22/90 -
AG 77/162 60.2 0.051 1.09(0.62-1.91) 0.760 77/162 46.0 0.085 1.07(0.58-1.97) 0.832
GG 25/81 33.9 0.037 1.59(1.01-2.50) 0.044 20/81 - 0.012 1.85(1.15-2.97) 0.011
AG+GG 102/243 39.0 0.012 1.43(1.31-2.22) 0.037 97/243 42.7 0.045 1.62(1.02-2.57) 0.042
IIIB AA 25/75 43.7 1.00 23/75 44.3 1.00
AG 114/221 30.1 0.032 1.59(1.02-2.48) 0.042 115/221 40.2 0.250 1.35(0.80-2.28) 0.267
GG 43/91 27.1 0.037 1.45(1.28-2.39) 0.031 36/91 33.2 0.009 1.86(1.18-2.94) 0.008
AG+GG 157/312 27.1 0.028 1.55(1.05-2.38) 0.029 151/312 33.7 0.019 1.69(1.09-2.65) 0.020
Treatment RT AA 23/71 - 1.00 22/71 48.4 1.00
AG 110/218 28.1 0.027 1.54(0.98-2.43) 0.059 111/218 41.7 0.167 1.39(0.82-2.36) 0.221
GG 44/91 30.1 0.019 1.49(1.19-2.48) 0.021 38/91 34.9 0.026 1.78(1.12-2.82) 0.015
AG+GG 154/309 29.0 0.035 1.53(1.08-2.38) 0.049 149/309 34.9 0.036 1.65(1.06-2.59) 0.028
CRT AA 27/94 61.4 1.00 23/94 - 1.00
AG 81/165 33.6 0.916 1.09(0.62-1.89) 0.772 81/165 35.1 0.869 0.99(0.53-1.85) 0.987
GG 24/81 - 0.029 1.58(1.02-2.46) 0.040 18/81 - 0.003 1.87(1.17-2.97) 0.009
AG+GG 105/246 34.5 0.039 1.43(1.02-2.20) 0.042 99/246 36.9 0.029 1.61(1.02-2.54) 0.041
Does ≥65Gy AA 24/85 - 1.00 23/85 48.4 1.00
AG 113/232 29.0 0.069 1.17(0.80-1.73) 0.420 114/232 41.7 0.799 1.23(0.82-1.86) 0.311
GG 46/102 30.1 0.014 1.31(1.23-1.32) 0.017 39/102 24.4 0.010 1.17(1.07-1.32) 0.020
AG+GG 159/334 29.2 0.013 1.25(1.18-1.93) 0.021 153/334 34.9 0.006 1.47(1.29-2.36) 0.013
<65Gy AA 26/80 59.3 1.00 22/80 - 1.00
AG 78/151 61.4 0.016 1.68(1.02-2.76) 0.041 78/151 35.5 0.133 1.54(0.91-2.58) 0.104
GG 22/70 33.6 0.039 1.70(1.09-2.66) 0..019 17/70 - 0.007 1.98(1.26-3.11) 0.003
AG+GG 100/221 38.7 0.014 1.70(1.10-2.61) 0.017 95/221 36.9 0.013 1.84(1.18-2.86) 0.007

Pa, Log-rank P; Pb, multivariate cox regression; MST, median survival time; RT, radiation therapy; CRT, chemoradiation therapy.